Thursday, June 24, 2021

New fly models with relevance to Multisystem Proteinopathy, ALS, and other valosin containig protein (VCP)-related diseases

"The power of a genetically tractable model organism coupled with well-established in vivo assays and a relatively short life cycle make Drosophila an attractive system to study VCP disease pathogenesis and novel treatment strategies."

Dis Model Mech. 2021 Jun 23:dmm.048603. doi: 10.1242/dmm.048603.

CRISPR/Cas9-engineered Drosophila knock-in models to study VCP diseases.

Wall JM, Basu A, Zunica ERM, Dubuisson OS, Pergola K, Broussard JP, Kirwan JP, Axelrod CL, Johnson AE

Abstract

"Valosin containing protein (VCP) is a hexameric type II AAA ATPase required for several cellular processes including ER-associated degradation, organelle biogenesis, autophagy and membrane fusion. VCP contains three domains: a regulatory N-terminal domain and two ATPase domains (D1 and D2). Mutations in the N-terminal and D1 domains are associated with several degenerative diseases, including Multisystem Proteinopathy (MSP-1) and ALS. However, patients with VCP mutations vary widely in their pathology and clinical penetrance, making it difficult to devise effective treatment strategies. Having a deeper understanding of how each mutation affects VCP function could enhance the prediction of clinical outcomes and design of personalized treatment options. Over-expressing VCP patient mutations in Drosophila has been shown to mimic many pathologies observed in human patients. The power of a genetically tractable model organism coupled with well-established in vivo assays and a relatively short life cycle make Drosophila an attractive system to study VCP disease pathogenesis and novel treatment strategies. Using CRISPR/Cas9, we have generated individual Drosophila knock-in mutants that include nine hereditary VCP disease mutations. We validate that these models display many hallmarks of VCP-mediated degeneration, including progressive decline in mobility, protein aggregate accumulation and defects in lysosomal and mitochondrial function. We also made some novel and unexpected findings, including laminopathies and sex-specific phenotypic differences in several mutants. Taken together, the Drosophila VCP disease models we have generated in this study will be useful for studying the etiology of individual VCP patient mutations and for testing potential genetic and/or pharmacological therapies."

DOI: 10.1242/dmm.048603
PMID: 34160014

Friday, June 18, 2021

Review article: "Discovering signaling mechanisms governing metabolism and metabolic diseases with Drosophila"

Cell Metab. 2021 Jun 11:S1550-4131(21)00269-2. doi: 10.1016/j.cmet.2021.05.018.

Discovering signaling mechanisms governing metabolism and metabolic diseases with Drosophila.

Kim SK, Tsao DD, Suh GSB, Miguel-Aliaga I]

Abstract:

There has been rapid growth in the use of Drosophila and other invertebrate systems to dissect mechanisms governing metabolism. New assays and approaches to physiology have aligned with superlative genetic tools in fruit flies to provide a powerful platform for posing new questions, or dissecting classical problems in metabolism and disease genetics. In multiple examples, these discoveries exploit experimental advantages as-yet unavailable in mammalian systems. Here, we illustrate how fly studies have addressed long-standing questions in three broad areas-inter-organ signaling through hormonal or neural mechanisms governing metabolism, intestinal interoception and feeding, and the cellular and signaling basis of sexually dimorphic metabolism and physiology-and how these findings relate to human (patho)physiology. The imaginative application of integrative physiology and related approaches in flies to questions in metabolism is expanding, and will be an engine of discovery, revealing paradigmatic features of metabolism underlying human diseases and physiological equipoise in health.

Copyright © 2021 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.cmet.2021.05.018
PMID: 34139200

Review article: Fly research & COVID-19

"Remarkably, 90% of the SARS-CoV-2 virus-host interacting proteins are conserved between Drosophila and humans."

 

Cell Biosci. 2021 Jun 13;11(1):110. doi: 10.1186/s13578-021-00621-5.

Drosophila, a powerful model to study virus-host interactions and pathogenicity in the fight against SARS-CoV-2

van de Leemput J, Han Z

Abstract:

"The COVID-19 pandemic is having a tremendous impact on humanity. Although COVID-19 vaccines are showing promising results, they are not 100% effective and resistant mutant SARS-CoV-2 strains are on the rise. To successfully fight against SARS-CoV-2 and prepare for future coronavirus outbreaks, it is essential to understand SARS-CoV-2 protein functions, their host interactions, and how these processes convey pathogenicity at host tissue, organ and systemic levels. In vitro models are valuable but lack the physiological context of a whole organism. Current animal models for SARS-CoV-2 research are exclusively mammals, with the intrinsic limitations of long reproduction times, few progeny, ethical concerns and high maintenance costs. These limitations make them unsuitable for rapid functional investigations of virus proteins as well as genetic and pharmacological screens. Remarkably, 90% of the SARS-CoV-2 virus-host interacting proteins are conserved between Drosophila and humans. As a well-established model system for studying human diseases, the fruit fly offers a highly complementary alternative to current mammalian models for SARS-CoV-2 research, from investigating virus protein function to developing targeted drugs. Herein, we review Drosophila's track record in studying human viruses and discuss the advantages and limitations of using fruit flies for SARS-CoV-2 research. We also review studies that already used Drosophila to investigate SARS-CoV-2 protein pathogenicity and their damaging effects in COVID-19 relevant tissues, as well as studies in which the fly was used as an efficient whole animal drug testing platform for targeted therapeutics against SARS-CoV-2 proteins or their host interacting pathways."

DOI: 10.1186/s13578-021-00621-5
PMCID: PMC8200282
PMID: 34120640

Tuesday, May 18, 2021

Seminar Series: Model organisms in human disease research

Of interest to blog readers: 

In a Genes to Genomes blog post May 17, 2021, the Genetics Society of America has announced a new seminar series on "Advancing both basic science and medicine by studying human disease genes in model organisms." The series includes talks that will be presented in the summer and fall of 2021.

 View seminar topics and register to attend at this page.



Thursday, April 29, 2021

Fly eye assay explored as a tool for assessing potential therapeutic treatments of chronic myeloid leukemia

Haematologica. 2020 Jan 31;105(2):387-397. doi: 10.3324/haematol.2019.219394. Print 2020.

Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening.

Outa AA, Abubaker D, Bazarbachi A, Sabban ME, Shirinian M, Nasr R

Abstract:

Chronic myeloid leukemia is caused by a balanced chromosomal translocation resulting in the formation of BCR-ABL1 fusion gene encoding a constitutively active BCR-ABL1 tyrosine kinase, which activates multiple signal transduction pathways leading to malignant transformation. Standard treatment of chronic myeloid leukemia is based on tyrosine kinase inhibitors; however, some mutations have proven elusive particularly the T315I mutation. Drosophila melanogaster is an established in vivo model for human diseases including cancer. The targeted expression of chimeric human/fly and full human BCR-ABL1 in Drosophila eyes has been shown to result in detrimental effects. In this study, we expressed human BCR-ABL1p210 and the resistant BCR-ABL1p210/T315I fusion oncogenes in Drosophila eyes. Expression of BCR-ABL1p210/T315I resulted in a severe distortion of the ommatidial architecture of adult eyes with a more prominent rough eye phenotype compared to milder phenotypes in BCR-ABL1p210 reflecting a stronger oncogenic potential of the mutant. We then assessed the efficacy of the currently used tyrosine kinase inhibitors in BCR-ABL1p210 and BCR-ABL1p210/T315I expressing flies. Treatment of BCR-ABL1p210 expressing flies with potent kinase inhibitors (dasatinib and ponatinib) resulted in the rescue of ommatidial loss and the restoration of normal development. Taken together, we provide a chronic myeloid leukemia tailored BCR-ABL1p210 and BCR-ABL1p210/T315I fly model which can be used to test new compounds with improved therapeutic indices.

DOI: 10.3324/haematol.2019.219394
PMCID: PMC7012492
PMID: 31101753

Study exploring impact of phophorylation state of PINK1 includes rescue of PINK1 definiciency in Drosophila as investigative tool (relevance to Parkinsons Disease)

EMBO Rep. 2020 Aug 5;21(8):e48686. doi: 10.15252/embr.201948686. Epub 2020 Jun 2.

PINK1 phosphorylates Drp1(S616) to regulate mitophagy-independent mitochondrial dynamics.

Han H, Tan J, Wang R, Wan H, He Y, Yan X, Guo J, Gao Q, Li J, Shang S, Chen F, Tian R, Liu W,
Liao L, Tang B, Zhang Z

Abstract:

Impairment of PINK1/parkin-mediated mitophagy is currently proposed to be the molecular basis of mitochondrial abnormality in Parkinson's disease (PD). We here demonstrate that PINK1 directly phosphorylates Drp1 on S616. Drp1S616 phosphorylation is significantly reduced in cells and mouse tissues deficient for PINK1, but unaffected by parkin inactivation. PINK1-mediated mitochondrial fission is Drp1S616 phosphorylation dependent. Overexpression of either wild-type Drp1 or of the phosphomimetic mutant Drp1S616D, but not a dephosphorylation-mimic mutant Drp1S616A, rescues PINK1 deficiency-associated phenotypes in Drosophila. Moreover, Drp1 restores PINK1-dependent mitochondrial fission in ATG5-null cells and ATG7-null Drosophila. Reduced Drp1S616 phosphorylation is detected in fibroblasts derived from 4 PD patients harboring PINK1 mutations and in 4 out of 7 sporadic PD cases. Taken together, we have identified Drp1 as a substrate of PINK1 and a novel mechanism how PINK1 regulates mitochondrial fission independent of parkin and autophagy. Our results further link impaired PINK1-mediated Drp1S616 phosphorylation with the pathogenesis of both familial and sporadic PD.

DOI: 10.15252/embr.201948686
PMCID: PMC7403662
PMID: 32484300

Report relevant to age-related disorders tests effects of treatment with alpha-lipoic acid on Drosophila

EMBO Rep. 2020 Aug 5;21(8):e49583. doi: 10.15252/embr.201949583. Epub 2020 Jul 9.

Lipoic acid rejuvenates aged intestinal stem cells by preventing age-associated endosome reduction.

Du G, Qiao Y, Zhuo Z, Zhou J, Li X, Liu Z, Li Y, Chen H

Comment in
EMBO Rep. 2020 Aug 5;21(8):e51175.

Abstract:

The age-associated decline of adult stem cell function is closely related to the decline in tissue function and age-related diseases. However, the underlying mechanisms that ultimately lead to the observed functional decline of stem cells still remain largely unexplored. This study investigated Drosophila midguts and found a continuous downregulation of lipoic acid synthase, which encodes the key enzyme for the endogenous synthesis of alpha-lipoic acid (ALA), upon aging. Importantly, orally administration of ALA significantly reversed the age-associated hyperproliferation of intestinal stem cells (ISCs) and the
observed decline of intestinal function, thus extending the lifespan of Drosophila. This study reports that ALA reverses age-associated ISC dysfunction by promoting the activation of the endocytosis-autophagy network, which decreases in aged ISCs. Moreover, this study suggests that ALA may be used as a safe and effective anti-aging compound for the treatment of ISC-dysfunction-related diseases and for the promotion of healthy aging in humans.

DOI: 10.15252/embr.201949583
PMCID: PMC7403706
PMID: 32648369